Surgical outcomes and risk factors for recurrence of myxopapillary ependymoma: a single-center experience
CONCLUSIONS: Findings of this study emphasize the importance of tumor size and location-particularly involvement of the sacral canal-in determining resectability. Reoperation for recurrence was necessary in 78% of patients with subtotally resected tumors; none of the patients who underwent GTR required reoperation. Most patients had stable neurological status postoperatively.PMID:37410596 | DOI:10.3171/2023.5.SPINE23433 (Source: Journal of Neurosurgery.Spine)
Source: Journal of Neurosurgery.Spine - July 6, 2023 Category: Neurosurgery Authors: Mark C Dougherty Mani Ratnesh S Sandhu Nahom Teferi Jennifer L Noeller Clayton L Rosinski Brian J Park Arnold H Menezes Kirill V Nourski Patrick W Hitchon Source Type: research
Surgical outcomes and risk factors for recurrence of myxopapillary ependymoma: a single-center experience
CONCLUSIONS: Findings of this study emphasize the importance of tumor size and location-particularly involvement of the sacral canal-in determining resectability. Reoperation for recurrence was necessary in 78% of patients with subtotally resected tumors; none of the patients who underwent GTR required reoperation. Most patients had stable neurological status postoperatively.PMID:37410596 | DOI:10.3171/2023.5.SPINE23433 (Source: Journal of Neurosurgery.Spine)
Source: Journal of Neurosurgery.Spine - July 6, 2023 Category: Neurosurgery Authors: Mark C Dougherty Mani Ratnesh S Sandhu Nahom Teferi Jennifer L Noeller Clayton L Rosinski Brian J Park Arnold H Menezes Kirill V Nourski Patrick W Hitchon Source Type: research
Surgical outcomes and risk factors for recurrence of myxopapillary ependymoma: a single-center experience
CONCLUSIONS: Findings of this study emphasize the importance of tumor size and location-particularly involvement of the sacral canal-in determining resectability. Reoperation for recurrence was necessary in 78% of patients with subtotally resected tumors; none of the patients who underwent GTR required reoperation. Most patients had stable neurological status postoperatively.PMID:37410596 | DOI:10.3171/2023.5.SPINE23433 (Source: Journal of Neurosurgery.Spine)
Source: Journal of Neurosurgery.Spine - July 6, 2023 Category: Neurosurgery Authors: Mark C Dougherty Mani Ratnesh S Sandhu Nahom Teferi Jennifer L Noeller Clayton L Rosinski Brian J Park Arnold H Menezes Kirill V Nourski Patrick W Hitchon Source Type: research
Surgical outcomes and risk factors for recurrence of myxopapillary ependymoma: a single-center experience
CONCLUSIONS: Findings of this study emphasize the importance of tumor size and location-particularly involvement of the sacral canal-in determining resectability. Reoperation for recurrence was necessary in 78% of patients with subtotally resected tumors; none of the patients who underwent GTR required reoperation. Most patients had stable neurological status postoperatively.PMID:37410596 | DOI:10.3171/2023.5.SPINE23433 (Source: Journal of Neurosurgery.Spine)
Source: Journal of Neurosurgery.Spine - July 6, 2023 Category: Neurosurgery Authors: Mark C Dougherty Mani Ratnesh S Sandhu Nahom Teferi Jennifer L Noeller Clayton L Rosinski Brian J Park Arnold H Menezes Kirill V Nourski Patrick W Hitchon Source Type: research
Surgical outcomes and risk factors for recurrence of myxopapillary ependymoma: a single-center experience
CONCLUSIONS: Findings of this study emphasize the importance of tumor size and location-particularly involvement of the sacral canal-in determining resectability. Reoperation for recurrence was necessary in 78% of patients with subtotally resected tumors; none of the patients who underwent GTR required reoperation. Most patients had stable neurological status postoperatively.PMID:37410596 | DOI:10.3171/2023.5.SPINE23433 (Source: Journal of Neurosurgery.Spine)
Source: Journal of Neurosurgery.Spine - July 6, 2023 Category: Neurosurgery Authors: Mark C Dougherty Mani Ratnesh S Sandhu Nahom Teferi Jennifer L Noeller Clayton L Rosinski Brian J Park Arnold H Menezes Kirill V Nourski Patrick W Hitchon Source Type: research
Cancers, Vol. 15, Pages 3429: WDR82-Mediated H3K4me3 Is Associated with Tumor Proliferation and Therapeutic Efficacy in Pediatric High-Grade Gliomas
Tadanori Tomita
Pediatric high-grade gliomas (pHGGs) are common malignant brain tumors without effective treatment and poor patient survival. Abnormal posttranslational modification at the histone H3 tail plays critical roles in tumor cell malignancy. We have previously shown that the trimethylation of lysine 4 at histone H3 (H3K4me3) plays a significant role in pediatric ependymoma malignancy and is associated with tumor therapeutic sensitivity. Here, we show that H3K4me3 and its methyltransferase WDR82 are elevated in pHGGs. A reduction in H3K4me3 by downregulating WDR82 decreases H3K4me3 promoter occupancy and the...
Source: Cancers - June 30, 2023 Category: Cancer & Oncology Authors: Nitin Wadhwani Sonali Nayak Yufen Wang Rintaro Hashizume Chunfa Jie Barbara Mania-Farnell Charles David James Guifa Xi Tadanori Tomita Tags: Article Source Type: research
Magnetic resonance imaging findings of intracranial extraventricular ependymoma: A retrospective multi ‐center cohort study of 114 cases
ConclusionWe identified specific MR imaging features such as tumor necrosis and thickness of enhancing tumor margins that could help to differentiate IEE from GBM. Our study results should be helpful to assist in diagnosis and clinical management of this rare brain tumor. (Source: Cancer Medicine)
Source: Cancer Medicine - June 28, 2023 Category: Cancer & Oncology Authors: Liyan Li,
Yan Fu,
Yinping Zhang,
Yipu Mao,
Deyou Huang,
Xiaoping Yi,
Jing Wang,
Zeming Tan,
Muliang Jiang,
Bihong T. Chen Tags: RESEARCH ARTICLE Source Type: research
The Role of Immunotherapy in the Treatment of Rare Central Nervous System Tumors
Curr Oncol. 2023 May 25;30(6):5279-5298. doi: 10.3390/curroncol30060401.ABSTRACTEstablishing novel therapies for rare central nervous system (CNS) tumors is arduous due to challenges in conducting clinical trials in rare tumors. Immunotherapy treatment has been a rapidly developing field and has demonstrated improvements in outcomes for multiple types of solid malignancies. In rare CNS tumors, the role of immunotherapy is being explored. In this article, we review the preclinical and clinical data of various immunotherapy modalities in select rare CNS tumors, including atypical meningioma, aggressive pituitary adenoma, pit...
Source: Current Oncology - June 27, 2023 Category: Cancer & Oncology Authors: Andrew Rodriguez Carlos Kamiya-Matsuoka Nazanin K Majd Source Type: research
The Role of Immunotherapy in the Treatment of Rare Central Nervous System Tumors
Curr Oncol. 2023 May 25;30(6):5279-5298. doi: 10.3390/curroncol30060401.ABSTRACTEstablishing novel therapies for rare central nervous system (CNS) tumors is arduous due to challenges in conducting clinical trials in rare tumors. Immunotherapy treatment has been a rapidly developing field and has demonstrated improvements in outcomes for multiple types of solid malignancies. In rare CNS tumors, the role of immunotherapy is being explored. In this article, we review the preclinical and clinical data of various immunotherapy modalities in select rare CNS tumors, including atypical meningioma, aggressive pituitary adenoma, pit...
Source: Current Oncology - June 27, 2023 Category: Cancer & Oncology Authors: Andrew Rodriguez Carlos Kamiya-Matsuoka Nazanin K Majd Source Type: research
